1	The	the	DT	_	2	det	_
2	companies	company	NNS	_	3	nsubj	3:A0=PAG
3	announced	announce	VBD	pb=announce.01	0	root	_
4	the	the	DT	_	8	det	_
5	expedited	expedite	VBN	p2=JJ|pb=expedite.01	8	amod	_
6	FDA	fda	NNP	_	8	nn	_
7	review	review	NN	p2=VBP	8	nn	_
8	classification	classification	NN	_	3	dobj	3:A1=PPT;5:A1=PPT
9	of	of	IN	_	8	prep	_
10	their	their	PRP$	_	12	poss	_
11	monoclonal	monoclonal	JJ	p2=JJS	12	amod	_
12	antibody	antibody	NN	_	9	pobj	_
13	Monday	monday	NNP	_	12	npadvmod	_
14	.	.	.	_	3	punct	_

1	The	the	DT	_	3	det	_
2	experimental	experimental	JJ	_	3	amod	_
3	drug	drug	NN	_	6	nsubjpass	6:A1
4	is	be	VBZ	_	6	aux	_
5	being	be	VBG	_	6	auxpass	_
6	investigated	investigate	VBN	pb=investigate.01	0	root	_
7	for	for	IN	_	6	prep	6:A2=PPT
8	use	use	NN	_	7	pobj	_
9	in	in	IN	_	8	prep	_
10	tandem	tandem	NN	_	9	pobj	_
11	with	with	IN	_	10	prep	_
12	lenalidomide	lenalidomide	NN	p2=JJ	11	pobj	_
13	and	and	CC	_	12	cc	_
14	dexamethasone	dexamethasone	NN	_	12	conj	_
15	for	for	IN	_	12	prep	_
16	patients	patient	NNS	_	15	pobj	20:A0=PAG
17	who	who	WP	_	20	nsubj	20:R-A0
18	have	have	VBP	_	20	aux	_
19	already	already	RB	_	20	advmod	20:AM-TMP
20	received	receive	VBN	pb=receive.01	16	rcmod	_
21	at	at	RB	p2=IN	22	advmod	_
22	least	least	RBS	_	23	advmod	_
23	one	#crd#	CD	_	26	num	_
24	or	or	CC	_	23	cc	_
25	two	#crd#	CD	_	23	conj	_
26	rounds	round	NNS	_	20	dobj	20:A1=PPT
27	of	of	IN	_	26	prep	_
28	prior	prior	JJ	p2=NN	29	amod	_
29	therapy	therapy	NN	_	27	pobj	_
30	.	.	.	_	6	punct	_

1	The	the	DT	_	2	det	_
2	companies	company	NNS	_	3	nsubj	3:A0
3	said	say	VBD	pb=say.01	0	root	_
4	the	the	DT	_	5	det	_
5	FDA	fda	NNP	_	6	nsubj	6:A0=PAG
6	handed	hand	VBD	pb=hand.02	3	ccomp	3:A1=PPT
7	over	over	RP	p2=IN	6	prt	6:C-V
8	the	the	DT	_	9	det	_
9	label	label	NN	_	6	dobj	6:A1=PPT;10:A1=PPT
10	based	base	VBN	pb=base.02	9	partmod	_
11	on	on	IN	_	10	prep	10:A2=DIR
12	open	open	JJ	_	14	hmod	_
13	-	-	HYPH	_	14	hyph	_
14	label	label	NN	_	18	nn	_
15	Phase	phase	NNP	p2=NN	17	hmod	_
16	-	-	HYPH	_	17	hyph	_
17	II	ii	NNP	_	18	nn	_
18	data	datum	NNS	p2=NN	11	pobj	_
19	.	.	.	_	3	punct	_

1	BMS	bm	NNS	p2=NNP	5	nsubj	5:A0
2	and	and	CC	_	1	cc	_
3	AbbVie	abbvie	NNP	_	1	conj	_
4	are	be	VBP	_	5	aux	_
5	co-developing	co-develop	VBG	pb=co-develop.01	0	root	_
6	the	the	DT	_	7	det	_
7	drug	drug	NN	_	5	dobj	5:A1
8	,	,	,	_	5	punct	_
9	and	and	CC	_	5	cc	_
10	BMS	bms	NNP	p2=NNPS	12	nsubj	12:A0
11	is	be	VBZ	_	12	aux	_
12	taking	take	VBG	pb=take.01	5	conj	_
13	the	the	DT	_	14	det	_
14	lead	lead	NN	_	12	dobj	12:A1=PPT
15	on	on	IN	_	14	prep	_
16	its	its	PRP$	_	17	poss	_
17	commercialization	commercialization	NN	_	15	pobj	_
18	.	.	.	_	12	punct	_

1	This	this	DT	_	2	det	_
2	material	material	NN	_	6	nsubjpass	6:A1=PRD;8:A1=PPT
3	may	may	MD	_	6	aux	6:AM-MOD;8:AM-MOD
4	not	not	RB	_	6	neg	6:AM-NEG;8:AM-NEG
5	be	be	VB	_	6	auxpass	_
6	published	publish	VBN	pb=publish.01	0	root	_
7	,	,	,	_	6	punct	_
8	broadcast	broadcast	VBN	p2=NN|pb=broadcast.01	6	conj	_
9	,	,	,	_	8	punct	_
10	rewritten	rewrite	VBN	pb=rewrite.01	8	conj	_
11	or	or	CC	_	10	cc	_
12	redistributed	redistribute	VBN	pb=redistribute.01	10	conj	_
13	in	in	IN	_	12	prep	12:AM-MNR
14	any	any	DT	_	15	det	_
15	form	form	NN	_	13	pobj	_
16	without	without	IN	_	12	prep	12:AM-MNR
17	prior	prior	JJ	_	18	amod	_
18	authorization	authorization	NN	_	16	pobj	_
19	.	.	.	_	6	punct	_

